Bristol-Myers Squibb (NYSE:BMY) Stock Unloaded Sen. Tommy Tuberville

Senator Tommy Tuberville (R-Alabama) recently sold shares of Bristol-Myers Squibb NYSE: BMY. In a filing disclosed on May 15th, the Senator disclosed that they had sold between $1,001 and $15,000 in Bristol-Myers Squibb stock on April 15th.

Senator Tommy Tuberville also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Duke Energy NYSE: DUK on 4/15/2025.
• Sold $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/15/2025.
• Sold $15,001 - $50,000 in shares of PayPal NASDAQ: PYPL on 4/15/2025.
• Sold $15,001 - $50,000 in shares of Constellation Brands NYSE: STZ on 4/15/2025.
• Sold $15,001 - $50,000 in shares of Alphabet NASDAQ: GOOGL on 4/15/2025.
• Sold $15,001 - $50,000 in shares of The Goldman Sachs Group NYSE: GS on 4/15/2025.
• Purchased $50,001 - $100,000 in shares of iShares Broad USD Investment Grade Corporate Bond ETF NASDAQ: USIG on 4/15/2025.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 4/15/2025.
• Sold $15,001 - $50,000 in shares of Mastercard NYSE: MA on 4/15/2025.
• Sold $15,001 - $50,000 in shares of Amgen NASDAQ: AMGN on 4/15/2025.

Bristol-Myers Squibb Stock Up 3.6%

BMY stock opened at $45.72 on Friday. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company's 50 day moving average is $53.35 and its two-hundred day moving average is $56.01. The stock has a market cap of $93.04 billion, a P/E ratio of -10.34, a PEG ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter last year, the company earned ($4.40) earnings per share. The firm's revenue for the quarter was down 5.6% on a year-over-year basis. Research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were issued a dividend of $0.62 per share. The ex-dividend date was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 5.42%. Bristol-Myers Squibb's payout ratio is currently 92.88%.

Institutional Investors Weigh In On Bristol-Myers Squibb

Institutional investors have recently made changes to their positions in the stock. Wealthspire Advisors LLC increased its stake in shares of Bristol-Myers Squibb by 0.6% in the 4th quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock valued at $1,622,000 after purchasing an additional 170 shares during the last quarter. Edmp Inc. grew its position in Bristol-Myers Squibb by 0.4% during the 4th quarter. Edmp Inc. now owns 41,599 shares of the biopharmaceutical company's stock worth $2,353,000 after acquiring an additional 171 shares during the last quarter. Trust Point Inc. lifted its holdings in Bristol-Myers Squibb by 1.9% during the 4th quarter. Trust Point Inc. now owns 9,423 shares of the biopharmaceutical company's stock worth $533,000 after buying an additional 172 shares during the period. Bedel Financial Consulting Inc. lifted its holdings in Bristol-Myers Squibb by 3.2% during the 4th quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company's stock worth $340,000 after buying an additional 175 shares during the period. Finally, Horst & Graben Wealth Management LLC lifted its holdings in Bristol-Myers Squibb by 2.4% during the 4th quarter. Horst & Graben Wealth Management LLC now owns 7,538 shares of the biopharmaceutical company's stock worth $426,000 after buying an additional 179 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The shares were bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares of the company's stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on BMY shares. UBS Group cut their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a report on Friday, February 7th. Finally, Citigroup lifted their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $58.00.

About Senator Tuberville

Tommy Tuberville (Republican Party) (also known as Coach) is a member of the U.S. Senate from Alabama. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Tuberville (Republican Party) ran for election to the U.S. Senate to represent Alabama. He won in the general election on November 3, 2020. Tuberville was head coach for several college football teams between 1995 and 2016, including at Auburn University and the University of Cincinnati. Tommy Tuberville was born in Camden, Arkansas, and lives in Auburn, Alabama. Tuberville's career experience includes working as a studio analyst with ESPN and as the head football coach of the University of Mississippi, the University of Auburn, Texas Tech University, and the University of Cincinnati.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.